Heart failure’s effects may reach deep into bone marrow
Heart failure is usually defined by the heart’s reduced ability to pump blood effectively. Research from a team led by scientists in Japan adds detail to another consequence: cardiac stress can alter the bone-marrow environment in ways that encourage long-lasting inflammatory changes in the immune system.
The work, published in Nature Communications, examined how heart failure affects the relationship between two cell populations in bone marrow. One consists of mesenchymal stromal cells, which help support blood-cell development. The other consists of hematopoietic stem and progenitor cells, the cells that generate blood and immune cells.
The researchers used mouse models and also analyzed human bone-marrow data. Their goal was to clarify how heart failure can create a durable form of innate immune memory in the bone marrow. That memory has been associated with the production of immune cells that promote inflammation and can worsen heart function, but the underlying process had remained unclear.
Identifying a protective cell population
The study focused on a subset of bone-marrow mesenchymal stromal cells marked by the leptin receptor, known as Lepr-positive MSCs. Under normal conditions, a subset of these cells produces heparin-binding epidermal growth factor-like growth factor, or HBEGF. The researchers describe these HBEGF-producing cells as guardians of the bone-marrow niche because they help sustain balanced blood-cell production.
A bone-marrow niche is the local cellular setting in which blood-forming stem and progenitor cells receive signals that influence how they behave and develop. The finding matters because it directs attention away from immune stem cells alone. It suggests that support cells surrounding those stem cells can relay the effects of stress originating in the heart.
In the mouse models, heart failure reduced this HBEGF-producing MSC population. At the same time, the condition promoted conversion of MSCs into adipocytes, or fat-forming cells. The loss of the HBEGF signal changed the development of hematopoietic stem and progenitor cells.
From cardiac stress to inflammatory immune output
The proposed sequence is a tissue-level chain reaction. Cardiac stress changes the bone-marrow niche; the protective HBEGF-producing stromal cells decline; blood-forming stem and progenitor cells then receive different signals; and the resulting immune-cell production is shifted toward inflammation-promoting cells.
This framework helps explain why heart failure can have consequences that persist beyond circulation. Rather than being solely an acute response to a failing pump, immune changes may be maintained through an altered bone-marrow environment. That is important for understanding the feedback loop described by the researchers: inflammation can contribute to worsening heart function, while heart failure can foster immune changes that sustain inflammation.
The team combined single-cell RNA sequencing, cell transplantation, molecular perturbation and analysis of human bone-marrow data. These methods allowed the scientists to study individual cell populations, test cellular roles and compare their findings with human data. The report does not establish a new treatment for people with heart failure, but it identifies a biological pathway that could be investigated further.
Why the result is significant
Heart failure affects more than the organ that gives the condition its name. The study supports the idea that the disease can reshape distant tissues that regulate immune-cell production. It also provides a more specific candidate mechanism than the broad observation that inflammation and heart failure are connected.
HBEGF and the Lepr-positive stromal-cell population are especially important in this account. If future work confirms how these signals operate in patients and whether they can be safely preserved or restored, the bone-marrow niche could become a target for approaches intended to limit harmful inflammatory programming. For now, that is a research direction, not a clinical recommendation.
The study’s experimental foundation includes mouse models, so its implications for human care require additional research. The inclusion of human bone-marrow data strengthens the relevance of the question, but it does not mean that findings in the animal models can be directly translated into a therapy. Researchers will need to establish how consistently the same cellular changes occur in people with heart failure, how they vary among patients, and whether modifying the pathway improves outcomes.
A broader view of cardiovascular disease
The work highlights the value of studying cardiovascular disease as a system-wide condition. The heart, immune system and bone marrow are linked through signals that can outlast an immediate episode of stress. Understanding those links may help researchers distinguish the mechanisms that merely accompany heart failure from those that help drive its progression.
For patients, the immediate message is not that bone-marrow testing should become routine. It is that investigators are refining the biological picture of why inflammation can remain active in heart failure. The newly identified loss of protective stromal “guardian” cells offers a focused hypothesis for the next stages of that work.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
